Population Pharmacokinetics of Cyclosporine after Hematopoietic Stem Cell Transplantation in Leukemic Patients
![]() |
Kim, Seung-Hee
(College of Pharmacy, Seoul National University)
Kim, Kyung-Im (College of Pharmacy, Seoul National University) Yun, Hwi-yeol (Drug Discovery Laboratory, Choongwae Pharma Corporation) Kang, Won-Ku (College of Pharmacy, Catholic University of Daegu) Yoon, Sung-Soo (Department of Internal Medicine, Seoul National University College of Medicine) Shin, Wan-Gyoon (College of Pharmacy, Seoul National University) Lee, Hye-Suk (Department of Pharmacy, Seoul National University Hospital) Oh, Jung-Mi (College of Pharmacy, Seoul National University) |
1 | Min DI, Lee M, Ku YM, et al., Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. Clin Pharmacol Ther 2000 Nov; 68(5): 478-486. DOI ScienceOn |
2 | Kahan BD, Kramer WG, Wideman C, et al., Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay. Transplantation. 1986; 41: 459-464. DOI ScienceOn |
3 | Yee GC, McGuire TR. Pharmacokinetic drug interactions with cyclosporin (Part I). Clin Pharmacokinet. 1990; 19: 319-332. DOI ScienceOn |
4 | Yee GC, Self SG, McGuire TR, et al., Serum cyclosporine concentration and risk of acute graft-versushost disease after allogeneic marrow transplantation. N Engl J Med. 1988; 319:65-70. DOI ScienceOn |
5 | Parkman R. Cyclosporine: GVHD and beyond. N Engl J Med. 1988; 319: 110-111. DOI ScienceOn |
6 | Przepiorka D, Shapiro S, Schwinghammer TL, et al., Cyclosporine and methylprednisolone after allogeneic marrow transplantation: Association between low cyclosporine concentration and risk of acute graft-versushost disease. Bone Marrow Transplant. 1991; 7: 461-465. |
7 | Schmidt H, Ehninger G, Dopfer R, et al., Correlation between low CSA plasma concentration and severity of acute GvHD in bone marrow transplantation. Blut. 1988; 57: 139-142. DOI ScienceOn |
8 | Armstrong VW, Oellerich M. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. Clin Biochem. 2001; 34(1): 9-16. DOI ScienceOn |
9 | Miller KB, Schenkein DP, Comenzo R, et al., Adjusteddose continuous-infusion cyclosporin A to prevent graftversus- host disease following allogeneic bone marrow transplantation. Ann Hematol. 1994; 68: 15-20. DOI ScienceOn |
10 | Gondo H, Harde M, Taniguchi S, et al., Cyclosporine combined with methylprednisolone or methotrexate in prophylaxis of moderate to severe acute graft-versus-host disease. Bone Marrow Transplant. 1993; 2: 437-441. |
11 | Abendroth D. Experience with therapeutic drug monitoring of cyclosporine. Transplant Proc. 2004; 36(2 Suppl): 426S-429S. DOI ScienceOn |
12 | Pichard L, Fabre I, Fabre G, et al., Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos. 1990; 18(5): 595-606. |
13 | McLachlan AJ, Tett SE. Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach.Ther Drug Monit. 1998; 20: 390-395. DOI ScienceOn |
14 | Yee GC, McGuire TR. Pharmacokinetic drug interactions with cyclosporin (Part II). Clin Pharmacokinet. 1990; 19: 400-415. DOI ScienceOn |
15 | Yates CR, Zhang W, Song P, et al., The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol. 2003; 43(6): 555-564. DOI |
16 | Yee GC, Kennedy MS, Storb R, et al., Effect of hepatic dysfunction on oral cyclosporin pharmacokinetics in marrow transplant patients. Blood. 1984; 64: 1277-1279. |
17 | Jones TE, Morris RG, Mathew TH. Diltiazem-cyclosporin pharmacokinetic interaction--dose-response relationship. Br J Clin Pharmacol. 1997; 44(5): 499-504. |
18 | Wu KH, Cui YM, Guo JF, et al., Population pharmacokinetics of cyclosporine in clinical renal transplant patients. Drug Metab Dispos. 2005; 33(9): 1268-1275. DOI ScienceOn |
19 | Charpiat, Bruno, Falconi, et al., A Population pharmacokinetic model of cyclosporine in the early postoperative phase in patients with liver transplants, and its predictive performance with bayesian fitting. Ther Drug Monit. 1998; 20(2): 158-164. DOI ScienceOn |
20 | Rosenbaum SE, Baheti G, Trull AK, et al., Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. Ther Drug Monit. 2005; 27(2): 116-122. DOI ScienceOn |
21 | Moyer TP, Johnson P, Faynor SM, et al., Cyclosporine: A review of drug monitoring problems and presentation of a simple, accurate liquid chromatographic procedure that solves these problems. Clin Biochem. 1986; 19: 83-89. DOI ScienceOn |
22 | Donatsch P, Abisch E, Homberger M, et al., A radioimmunoassay to measure cyclosporin A in plasma and serum samples. J Immunoassay. 1981; 2: 19-32. DOI |
23 | Rui JZ, Zhuo HT, Jiang GH, et al., Evaluation of population pharmacokinetics of cyclosporin A in renal transplantation patients with NONMEM, Yao Xue Xue Bao. 1995; 30(4): 241-247. |
24 | Shibata N, Hayakawa T, Hoshino N, et al., A predictive model for area under the concentration versus time curve of cyclosporin A using several routine monitoring results in renal transplant patients. Biol Pharm Bull. 1997; 20(8): 897-903. DOI ScienceOn |
25 | Yee GC, McGuire TR, Gmur DJ, et al., Blood cyclosporine pharmacokinetics in patients undergoing marrow transplantation Influence of age, obesity, and hematocrit. Transplantation.1988; 46: 399-402. DOI ScienceOn |
26 | Molpeceres J, Chacon M, Guzman M, et al., Dependency of cyclosporine tissue distribution and metabolism on the age and gender of rats after a single intravenous dose. Int J Pharm. 2000 Mar 20; 197(1-2): 129-141. DOI |
27 | Jacobson PA, Fuki NG, Kathlenn GE, et al., Posttansplant day significantly influences pharmacokinetics of cyclosporine after hematopoietic stem cell transplantation. Biology of blood and marrow transplantation 2003: 9: 304-311. DOI ScienceOn |
28 | Kennedy MS, Yee GC, McGuire TR, et al., Correlation of serum cyclosporine concentration with renal dysfunction in marrow transplant recipients. Transplantation. 1985; 40: 249- 253. DOI ScienceOn |
29 | Lindholm A, Ringden O, Lonnqvist B. The role of cyclosporine dosage and plasma levels in efficacy and toxicity in bone marrow transplant recipients. Transplantation. 1987; 43: 680-684. DOI ScienceOn |
30 | Beal L, SL. NONMEM User Guide. 1992, San Francisco, CA: NONMEM Project Group, UCSF. |
31 | Schultz KR, Nevill TJ, Joze CL, et al., The pharmacokinetics of oral cyclosporin A (Neoral) during the first month after bone marrow transplantation. Transplant Proc. 1998; 30: 1668-1670. DOI ScienceOn |
32 | Kasiske BL, Heim-Duthoy K, Rao KV, et al., The relationship between cyclosporine pharmacokinetic parameters and subsequent acute rejection in renal transplant recipients. Transplantation. 1988 Nov; 46(5): 716-722. DOI ScienceOn |
![]() |